AbbVie, Umoja Biopharma Set CAR-T Cell Therapies Collaboration
By Colin Kellaher
AbbVie has struck a pair of exclusive option and license agreements with clinical-stage biotechnology company Umoja Biopharma aimed at developing new chimeric antigen receptor T-cell, or CAR-T, cancer therapy candidates.
AbbVie on Thursday said the companies plan to develop multiple in-situ generated CAR-T cell therapy candidates using Umoja's proprietary VivoVec platform.
AbbVie said it made upfront payments and an equity investment in Umoja, which is eligible to receive up to $1.44 billion for option exercise fees, development and regulatory milestones, along with additional sales-based milestones and royalties on sales.
AbbVie said it has an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates, including Umoja's lead clinical program for hematologic malignancies, which is currently at the IND-enabling phase.
The companies also plan to develop up to four additional candidates for discovery targets selected by AbbVie, based in North Chicago, Ill.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 04, 2024 09:14 ET (14:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk